Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Detalles Bibliográficos
Autores principales: Wu, Huai-liang, Luo, Zi-yin, He, Zong-lin, Gong, Yue, Mo, Miao, Ming, Wai-kit, Liu, Guang-yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938255/
https://www.ncbi.nlm.nih.gov/pubmed/36717677
http://dx.doi.org/10.1038/s41416-023-02159-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938255/
https://www.ncbi.nlm.nih.gov/pubmed/36717677
http://dx.doi.org/10.1038/s41416-023-02159-4

Ejemplares similares